SCHEMBL855780

SCHEMBL855780

Clc1cc(N2CCOCC2)nc(OC2CCOCC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
MAPT P10636 1/20 0.55
KMT2A Q03164 4/20 0.51
AKT1 P31749 1/20 0.43
PIK3CA P42336 1/20 0.43
MTOR P42345 1/20 0.43
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
LRRK2 Q5S007 3/20 0.39
PDE10A Q9Y233 2/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28932018 0.83 CYP1A2 (0.46) CYP1A2CYP2D6MAPTKMT2AAKT1
SCHEMBL29359021 0.83 CYP1A2 (0.46) CYP1A2CYP2D6MAPTKMT2AAKT1
SCHEMBL856369 0.81 PDE10A (0.46) CYP1A2CYP2D6MAPTKMT2AAKT1
SCHEMBL18399090 0.80 CYP1A2 (0.60) CYP1A2CYP2D6MAPTKMT2ARAF1
SCHEMBL23763177 0.79 KRAS (0.36) CYP1A2CYP2D6MAPTKMT2AAKT1
SCHEMBL29968495 0.78 ALDH1A1 (0.43) CYP1A2CYP2D6KMT2AMEN1CYP2C19
SCHEMBL23763096 0.78 ALDH1A1 (0.43) CYP1A2CYP2D6KMT2AMEN1CYP2C19
SCHEMBL2815691 0.78 PDE10A (0.46) CYP1A2CYP2D6MAPTKMT2APIK3CA
SCHEMBL16094599 0.76 PIK3CD (0.44) CYP1A2CYP2D6MAPTKMT2AAKT1
SCHEMBL18398916 0.76 CYP1A2 (0.56) CYP1A2CYP2D6MAPTKMT2ARAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173647-B2 PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-08 US disclosed
US-8173647-B2 PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-08 US disclosed
US-8173647-B2 PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-08 US disclosed
EP-2118087-B1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-03-28 EP disclosed
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2010-02-25 US disclosed
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2010-02-25 US disclosed
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2010-02-25 US disclosed
EP-2118087-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE Novartis Ag (CH) 2009-11-18 EP disclosed
WO-2008098058-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE PI4KA, PI4KB, PI4K2A CYP1A2 4501/4885CYP2D6 4810/4885MAPT 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.